Please login to the form below

Not currently logged in
Email:
Password:

uterine fibroid

This page shows the latest uterine fibroid news and features for those working in and with pharma, biotech and healthcare.

Bayer moves vilaprisan into phase III trials for uterine fibroids

Bayer moves vilaprisan into phase III trials for uterine fibroids

Uterine fibroids are the most common benign gynecological tumors, with approximately 5-10% of women requiring treatment for the disease. ... Meanwhile, Allergan and Gedeon Richter plan to file their uterine fibroid drug ulipristal acetate in the US by

Latest news

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics